Beinaglutide Shows Significantly Beneficial Effects in Diabetes/Obesity-Induced Nonalcoholic Steatohepatitis in Ob/Ob Mouse Model
Dedicated under-eye microinfusion patches sized for the periorbital area work better than facial stamps
Slows Gastric Emptying: GLP-1 slows down the rate at which food leaves the stomach

UK considerations NHS and MHRA guidance The UK health authorities have clear positions on weight loss treatments: The NHS offers GLP-1 medications through specialist weight management services for eligible patients MHRA has approved Wegovy, Saxenda, and Mounjaro based on comprehensive safety and efficacy data No GLP-1 patch products have received MHRA approval as weight loss treatments The MHRA has issued warnings about misleading claims in weight loss supplements Cost and access in the UK The financial aspect is a significant consideration for many: NHS provision : Limited availability through specialist weight management services with strict eligibility criteria Private prescriptions : 150-300 monthly, depending on medication and provider Commercial patches : 12-70 monthly, depending on brand and quantity While patches appear less expensive, they lack evidence of effectiveness, making them poor value regardless of price
Benge explains
Patients who may particularly benefit from the oral option include: Those with needle concerns: While modern GLP-1 injections use very small needles, some patients have significant needle phobia that prevents them from starting treatment Patients seeking a less medical approach: Some individuals prefer the familiarity of taking a daily pill over self-injecting Weight maintenance candidates: Emerging research suggests oral GLP-1s may be effective for maintaining weight loss after achieving goals on injectable medications Those with access challenges: Pills dont require refrigeration and may be easier to travel with Important Considerations Before Switching or Starting The Wegovy pill will be available in January 2026, with the starting 1.5mg dose priced at $149 per month for cash-paying patients